DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
基本信息
- 批准号:3180917
- 负责人:
- 金额:$ 23.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-07-01 至 1994-01-31
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyte Burkitt's lymphoma DNA directed RNA polymerase DNA footprinting Retroviridae adenocarcinoma bioassay cell transformation chromosome translocation gel electrophoresis gene deletion mutation gene expression gene rearrangement gene therapy genetic enhancer element genetic mapping genetic transcription human population genetics hybrid cells immunoglobulin genes lac operon major histocompatibility complex molecular cloning molecular oncology neoplasm /cancer genetics neoplastic cell culture for noncancer research nucleic acid probes nucleic acid sequence oncogenes point mutation protooncogene tissue /cell culture transfection transposon /insertion element
项目摘要
The long range objective of this proposal is to elucidate the
importance of two classes of mechanisms of deregulation of proto-
oncogenes in human tumors; that is, mutations in the proto-
oncogenes itself (cis-acting) and mutations in trans-acting
regulators. The studies focus on c-myc because this gene is
expressed in many different types of human tumors. What is the
importance of c-myc expression in these tumors? The expression is
presumed to be due to mutation that affect the myc regulatory
circuit. What are the different types of mutations that have this
effect? The aims of this proposal include an analysis of cis-
acting alterations in two different myc loci clones from human
tumors. In one case, a LINE-1 sequence (one of a family of
repetitive transposable elements present in thousands of copies in
the human genome) has become inserted into intron 2 of myc. The
insertion is tumor specific. The insertion will be cloned and
sequenced and analyzed for the presence of enhancer elements and
for the capacity to code for proteins involved in the process of
transposition. The second locus under study produces myc message
levels 50 times greater than those found in normal leukocytes.
The locus contains multiple deletions, insertions, duplications,
and point mutations. The exact role of each of these aberrations
in the deregulation will e determine. A second aim of this
proposal is to analyze trans-acting alterations that result in
deregulation of c-myc in two thirds of human adenocarcinomas of the
colon. Experiments employing somatic cell hybrids between cells
expressing regulated c-myc and colon carcinoma cells expressing
deregulated myc result in hybrid cells in which myc is regulated
normally. A working hypothesis, based on the results of this
experiments, is that genetic defects in the colon carcimona cell
parent have inactivated both alleles of a trans-acting locus that
regulates myc (such as a repressor) and that the defects are
complemented by an intact locus in the parent expressing regulated
myc. These experiments will be pursued to determine how many such
trans-acting loci there might be, what human chromosomes they map
to, an what the molecular mechanism is by which lesions in these
loci result in deregulation of c-myc. This work might ultimately
have clinical significance in that the normal alleles of these
genes could be cloned and supplied to the tumor cells through the
use of suitable vectors such aS retroviruses. Through the use of
such "gene transplant therapy" the transformed phenotype of the
tumor cells might be reversed.
本建议的长远目标是阐明
两类机制的重要性解除管制的原,
人类肿瘤中的癌基因;也就是说,原癌基因中的突变,
癌基因本身(顺式作用)和反式作用突变
监管部门 这些研究集中在c-myc上,因为这个基因是
在许多不同类型的人类肿瘤中表达。 是什么
c-myc表达在这些肿瘤中的重要性? 表情
推测是由于突变影响myc调节
电路. 有哪些不同类型的突变
效果如何? 本建议的目的包括分析顺-
人两个不同myc基因座克隆的作用改变
肿瘤的 在一种情况下,LINE-1序列(LINE-1家族中的一个)可以被插入。
重复的转座因子存在于数千个拷贝中,
人类基因组)已经插入到myc的内含子2中。 的
插入是肿瘤特异性的。 插入将被克隆,
测序并分析增强子元件的存在,
编码蛋白质的能力
换位 研究中的第二个位点产生myc信息
比正常白细胞高50倍。
该基因座包含多个缺失,插入,重复,
和点突变 这些畸变的确切作用
在放松管制将决定。 第二个目的是
建议是分析导致
在三分之二的人乳腺癌中c-myc的失调
结肠 使用细胞间体细胞杂交的实验
表达调控的c-myc和表达调控的c-myc的结肠癌细胞
myc的失调导致了myc受到调节的杂交细胞
正常情况下 一个工作假设,基于这个结果,
实验中,结肠癌细胞中的遗传缺陷
亲本已经失活了反式作用基因座的两个等位基因,
调节myc(如阻遏物),缺陷是
由亲本中表达受调节的
Myc。 这些实验将继续进行,以确定有多少这样的
可能存在的反式作用基因座,它们绘制的人类染色体
这些病变的分子机制是什么
基因座导致c-myc的失调。 这项工作最终可能
具有临床意义,因为这些正常等位基因
基因可以被克隆,并通过
使用合适的载体,例如逆转录病毒。 通过使用
这种“基因移植疗法”是指通过基因移植治疗,
肿瘤细胞可以逆转。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUSAN M ASTRIN其他文献
SUSAN M ASTRIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUSAN M ASTRIN', 18)}}的其他基金
DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
- 批准号:
3180922 - 财政年份:1985
- 资助金额:
$ 23.03万 - 项目类别:
DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
- 批准号:
2090298 - 财政年份:1985
- 资助金额:
$ 23.03万 - 项目类别:
DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
- 批准号:
3180921 - 财政年份:1985
- 资助金额:
$ 23.03万 - 项目类别:
DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
- 批准号:
3180919 - 财政年份:1985
- 资助金额:
$ 23.03万 - 项目类别:
DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
- 批准号:
3180920 - 财政年份:1985
- 资助金额:
$ 23.03万 - 项目类别:
DEREGULATION OF ONCOGENE EXPRESSION IN HUMAN TUMORS
人类肿瘤中癌基因表达的失调
- 批准号:
3180923 - 财政年份:1985
- 资助金额:
$ 23.03万 - 项目类别:
相似海外基金
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
- 批准号:
8653055 - 财政年份:2014
- 资助金额:
$ 23.03万 - 项目类别:
The role of activation-induced cytidine deaminase (AID) mediated DNA damage in the pathogenesis of Burkitt's Lymphoma
活化诱导胞苷脱氨酶 (AID) 介导的 DNA 损伤在伯基特淋巴瘤发病机制中的作用
- 批准号:
258438392 - 财政年份:2014
- 资助金额:
$ 23.03万 - 项目类别:
Research Fellowships
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
- 批准号:
8788701 - 财政年份:2014
- 资助金额:
$ 23.03万 - 项目类别:
The interaction of Burkitt's lymphoma cofactors EBV and Plasmodium
伯基特淋巴瘤辅助因子 EBV 和疟原虫的相互作用
- 批准号:
8846480 - 财政年份:2012
- 资助金额:
$ 23.03万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7289830 - 财政年份:2006
- 资助金额:
$ 23.03万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7097879 - 财政年份:2006
- 资助金额:
$ 23.03万 - 项目类别:
REGULATION OF EBV TRANSCRIPTION IN BURKITT'S LYMPHOMA
伯基特淋巴瘤中 EBV 转录的调控
- 批准号:
7349162 - 财政年份:2006
- 资助金额:
$ 23.03万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7684750 - 财政年份:2006
- 资助金额:
$ 23.03万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7492826 - 财政年份:2006
- 资助金额:
$ 23.03万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7935180 - 财政年份:2006
- 资助金额:
$ 23.03万 - 项目类别:














{{item.name}}会员




